Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (2774) 2774
humans (2731) 2731
science & technology (1818) 1818
life sciences & biomedicine (1786) 1786
middle aged (1407) 1407
fallopian tube neoplasms - pathology (1371) 1371
adult (1208) 1208
aged (917) 917
ovarian neoplasms - pathology (916) 916
obstetrics & gynecology (903) 903
oncology (783) 783
biological and medical sciences (664) 664
medical sciences (654) 654
tumors (601) 601
ovarian cancer (592) 592
fallopian tubes - pathology (573) 573
fallopian tube (509) 509
pathology (507) 507
gynecology. andrology. obstetrics (503) 503
fallopian tube neoplasms - surgery (472) 472
neoplasm staging (447) 447
female genital diseases (425) 425
fallopian tubes - surgery (416) 416
cancer (411) 411
hysterectomy (362) 362
ovarian neoplasms - surgery (361) 361
ovariectomy (355) 355
retrospective studies (322) 322
abridged index medicus (320) 320
fallopian tube neoplasms - diagnosis (316) 316
adenocarcinoma - pathology (301) 301
peritoneal neoplasms - pathology (291) 291
surgery (284) 284
prognosis (283) 283
ovarian neoplasms - genetics (279) 279
aged, 80 and over (271) 271
immunohistochemistry (262) 262
fallopian tube neoplasms - drug therapy (258) 258
diagnosis, differential (255) 255
obstetrics and gynecology (245) 245
pregnancy (244) 244
fallopian tubes (235) 235
cystadenocarcinoma, serous - pathology (232) 232
fallopian tube neoplasms - genetics (230) 230
ovarian neoplasms - drug therapy (226) 226
treatment outcome (225) 225
uterine neoplasms - pathology (212) 212
chemotherapy (208) 208
animals (190) 190
fallopian tube neoplasms - therapy (190) 190
mutation (190) 190
ovarian neoplasms - diagnosis (181) 181
antineoplastic combined chemotherapy protocols - therapeutic use (180) 180
follow-up studies (168) 168
hematology, oncology and palliative medicine (166) 166
carcinoma (163) 163
fallopian tube neoplasms - mortality (162) 162
ovary - pathology (158) 158
peritoneal neoplasms - drug therapy (158) 158
adolescent (152) 152
risk factors (149) 149
carcinoma - pathology (147) 147
endometrial neoplasms - pathology (142) 142
survival rate (142) 142
research (140) 140
diagnosis (136) 136
laparoscopy (135) 135
analysis (133) 133
ovarian neoplasms - metabolism (131) 131
ovary (130) 130
carcinoma, ovarian epithelial (127) 127
care and treatment (127) 127
fallopian tube neoplasms - complications (127) 127
combined modality therapy (126) 126
health aspects (126) 126
metastasis (126) 126
neoplasms, glandular and epithelial - pathology (123) 123
carcinoma in situ - pathology (122) 122
female genital diseases and pregnancy complications (121) 121
gynecology (120) 120
disease-free survival (119) 119
genes, brca1 (118) 118
peritoneal neoplasms - surgery (117) 117
ovarian carcinoma (116) 116
ovarian neoplasms - mortality (113) 113
adenocarcinoma - surgery (112) 112
endometriosis - pathology (112) 112
fallopian tube neoplasms - metabolism (112) 112
neoplasm grading (112) 112
cystadenocarcinoma, serous - genetics (110) 110
young adult (110) 110
genes, brca2 (105) 105
fallopian tube carcinoma (103) 103
medicine & public health (103) 103
neoplasm metastasis (103) 103
genetic aspects (102) 102
uterine cervical neoplasms - pathology (101) 101
fallopian tubes - metabolism (100) 100
uterine neoplasms - surgery (100) 100
chemotherapy, adjuvant (98) 98
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2716) 2716
German (81) 81
French (58) 58
Polish (27) 27
Chinese (24) 24
Russian (22) 22
Spanish (22) 22
Italian (21) 21
Japanese (21) 21
Bulgarian (15) 15
Czech (7) 7
Danish (5) 5
Hebrew (4) 4
Hungarian (4) 4
Dutch (3) 3
Croatian (2) 2
Korean (1) 1
Portuguese (1) 1
Romanian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
by Swisher, Elizabeth M, Dr Prof and Lin, Kevin K, PhD and Oza, Amit M, Prof and Scott, Clare L, PhD and Giordano, Heidi, MA and Sun, James, PhD and Konecny, Gottfried E, MD and Coleman, Robert L, Prof and Tinker, Anna V, MD and O'Malley, David M, MD and Kristeleit, Rebecca S, MD and Ma, Ling, MD and Bell-McGuinn, Katherine M, MD and Brenton, James D, Prof and Cragun, Janiel M, MD and Oaknin, Ana, MD and Ray-Coquard, Isabelle, Prof and Harrell, Maria I, PhD and Mann, Elaina, MS and Kaufmann, Scott H, Prof and Floquet, Anne, MD and Leary, Alexandra, MD and Harding, Thomas C, PhD and Goble, Sandra, MS and Maloney, Lara, BA and Isaacson, Jeff, PhD and Allen, Andrew R, MD and Rolfe, Lindsey, MBChB and Yelensky, Roman, PhD and Raponi, Mitch, PhD and McNeish, Iain A, Prof
The lancet oncology, ISSN 1470-2045, 2016, Volume 18, Issue 1, pp. 75 - 87
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)
by McCluggage, W. Glenn and Judge, Meagan J and Clarke, Blaise A and Davidson, Ben and Gilks, C. Blake and Hollema, Harry and Ledermann, Jonathan A and Matias-Guiu, Xavier and Mikami, Yoshiki and Stewart, Colin J. R and Vang, Russell and Hirschowitz, Lynn and International Collaboration on Cancer Reporting
Modern pathology, ISSN 0893-3952, 08/2015, Volume 28, Issue 8, pp. 1101 - 1122
Life Sciences & Biomedicine | Pathology | Science & Technology | Predictive Value of Tests | Humans | Ovarian Neoplasms - pathology | Immunohistochemistry - standards | Carcinoma - chemistry | Peritoneal Neoplasms - chemistry | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - chemistry | Fallopian Tube Neoplasms - genetics | Female | Molecular Diagnostic Techniques - standards | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Carcinoma - pathology | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Pathology, Clinical - standards | Diagnosis, Differential | Ovarian Neoplasms - chemistry | Biopsy - standards | Biomarkers, Tumor - analysis | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Fallopian Tube Neoplasms - pathology | Fallopian Tube Neoplasms - surgery | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Research Design - standards | Biomarkers, Tumor - genetics | Neoplasm Staging | Ovarian Neoplasms - surgery | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
by Kindelberger, David W and Lee, Yonghee and Miron, Alexander and Hirsch, Michelle S and Feltmate, Colleen and Medeiros, Fabiola and Callahan, Michael J and Garner, Elizabeth O and Gordon, Robert W and Birch, Chandler and Berkowitz, Ross S and Muto, Michael G and Crum, Christopher P
The American journal of surgical pathology, ISSN 0147-5185, 02/2007, Volume 31, Issue 2, pp. 161 - 169
Serous carcinoma | BRCA | Fallopian tube neoplasms | Ovarian neoplasms | Intraepithelial carcinoma | Pathology | Life Sciences & Biomedicine | Surgery | Science & Technology | Biological and medical sciences | Investigative techniques, diagnostic techniques (general aspects) | Medical sciences | Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques | Humans | Cystadenocarcinoma, Serous - metabolism | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - pathology | Ovarian Neoplasms - genetics | Carcinoma in Situ - genetics | Fallopian Tube Neoplasms - genetics | Female | Ovarian Neoplasms - metabolism | Neoplasms, Second Primary - genetics | Pelvic Neoplasms - pathology | Peritoneal Neoplasms - pathology | Carcinoma in Situ - pathology | Pelvic Neoplasms - genetics | Tumor Suppressor Protein p53 - metabolism | Fallopian Tube Neoplasms - pathology | Genes, p53 - genetics | Neoplasms, Second Primary - metabolism | Peritoneal Neoplasms - genetics | Peritoneal Neoplasms - metabolism | Fallopian Tube Neoplasms - metabolism | Mutation | Carcinoma in Situ - metabolism | Precancerous Conditions | Neoplasms, Second Primary - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
by Katsumata, Noriyuki, Prof and Yasuda, Makoto, Prof and Isonishi, Seiji, Prof and Takahashi, Fumiaki, PhD and Michimae, Hirofumi, PhD and Kimura, Eizo, MD and Aoki, Daisuke, Prof and Jobo, Toshiko, MD and Kodama, Shoji, MD and Terauchi, Fumitoshi, Prof and Sugiyama, Toru, Prof and Ochiai, Kazunori, Prof and for the Japanese Gynecologic Oncology Group and Japanese Gynecologic Oncology Grp and Japanese Gynecologic Oncology Group
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 1020 - 1026
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Humans | Ovarian Neoplasms - pathology | Proportional Hazards Models | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Ovarian Neoplasms - mortality | Peritoneal Neoplasms - mortality | Disease-Free Survival | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - mortality | Neoplasms, Glandular and Epithelial - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Female | Neoplasm Staging | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
by Ursula A. Matulonis and Suzanne Berlin and Percy Ivy and Karin Tyburski and Carolyn Krasner and Corrine Zarwan and Anna Berkenblit and Susana Campos and Neil Horowitz and Stephen A. Cannistra and Hang Lee and Julie Lee and Maria Roche and Margaret Hill and Christin Whalen and Laura Sullivan and Chau Tran and Benjamin D. Humphreys and Richard T. Penson
Journal of clinical oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5601 - 5606
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Biological and medical sciences | Medical sciences | Tumors | Female genital diseases | Prognosis | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Peritoneal Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - mortality | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Quinazolines - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Drug Administration Schedule | Risk Assessment | Administration, Oral | Fallopian Tube Neoplasms - pathology | Treatment Outcome | Peritoneal Neoplasms - mortality | Disease-Free Survival | Maximum Tolerated Dose | Fallopian Tube Neoplasms - mortality | Neoplasms, Glandular and Epithelial - drug therapy | Quinazolines - adverse effects | Survival Analysis | Aged | Index Medicus | Original Reports | Gync19
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Fallopian tube precursors of ovarian low‐ and high‐grade serous neoplasms
by Vang, Russell and Shih, Ie‐Ming and Kurman, Robert J
Histopathology, ISSN 0309-0167, 01/2013, Volume 62, Issue 1, pp. 44 - 58
high‐grade serous carcinoma | ovary | fallopian tube | serous borderline tumour | serous tubal intra‐epithelial carcinoma | Serous tubal intra-epithelial carcinoma | Ovary | Fallopian tube | Serous borderline tumour | High-grade serous carcinoma | Pathology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Fallopian Tubes - pathology | Humans | Ovarian Neoplasms - pathology | Fallopian Tube Neoplasms - pathology | Female | Precancerous Conditions - pathology | Cystadenocarcinoma, Serous - pathology | Disease Progression | Cystadenoma, Serous - pathology | Tumors | Birth control | Pathogenesis | Reproductive system | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
by Peter C. Fong and Timothy A. Yap and David S. Boss and Craig P. Carden and Marja Mergui-Roelvink and Charlie Gourley and Jacques De Greve and Jan Lubinski and Susan Shanley and Christina Messiou and Roger A'Hern and Andrew Tutt and Alan Ashworth and John Stone and James Carmichael and Jan H.M. Schellens and Johann S. de Bono and Stan B. Kaye
Journal of clinical oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15, pp. 2512 - 2519
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Biological and medical sciences | Medical sciences | Tumors | Female genital diseases | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Pharmacogenetics | Fallopian Tube Neoplasms - enzymology | Fallopian Tube Neoplasms - pathology | Piperazines - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | Peritoneal Neoplasms - enzymology | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - genetics | Peritoneal Neoplasms - genetics | Cell Line, Tumor | Aged | Neoplasm Staging | Phthalazines - adverse effects | Cohort Studies | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation
by Finch, Amy P M and Finch, Amy P. M and Lubinski, Jan and Lubinski, Jan and Møller, Pål and Møller, Pål and Singer, Christian F and Singer, Christian F and Karlan, Beth and Karlan, Beth and Senter, Leigha and Senter, Leigha and Rosen, Barry and Rosen, Barry and Maehle, Lovise and Maehle, Lovise and Ghadirian, Parviz and Ghadirian, Parviz and Cybulski, Cezary and Cybulski, Cezary and Huzarski, Tomasz and Huzarski, Tomasz and Eisen, Andrea and Eisen, Andrea and Foulkes, William D and Foulkes, William D and Kim-Sing, Charmaine and Kim-Sing, Charmaine and Ainsworth, Peter and Ainsworth, Peter and Tung, Nadine and Tung, Nadine and Lynch, Henry T and Lynch, Henry T and Neuhausen, Susan and Neuhausen, Susan and Metcalfe, Kelly A and Metcalfe, Kelly A and Thompson, Islay and Thompson, Islay and Murphy, Joan and Murphy, Joan and Sun, Ping and Sun, Ping and Narod, Steven A and Narod, Steven A
Journal of clinical oncology, ISSN 0732-183X, 2014, Volume 32, Issue 15, pp. 1547 - 1553
Life Sciences & Biomedicine | Oncology | Science & Technology | Ovariectomy - adverse effects | Age Factors | Humans | Middle Aged | Ovarian Neoplasms - pathology | Ovarian Neoplasms - mortality | North America | Incidence | Ovarian Neoplasms - genetics | Time Factors | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Adult | Female | Registries | Surveys and Questionnaires | Odds Ratio | Peritoneal Neoplasms - pathology | Fallopian Tube Neoplasms - prevention & control | Genetic Predisposition to Disease | Ovarian Neoplasms - prevention & control | Risk Assessment | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Fallopian Tube Neoplasms - pathology | Treatment Outcome | Peritoneal Neoplasms - prevention & control | Peritoneal Neoplasms - mortality | BRCA1 Protein - genetics | Ovariectomy - mortality | Phenotype | Fallopian Tube Neoplasms - mortality | Peritoneal Neoplasms - genetics | Aged | Mutation | BRCA2 Protein - genetics | Index Medicus | Gync21 | Bios4 | Bc3 | ORIGINAL REPORTS | Gync15
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer
by Zeppernick, F and Meinhold-Heerlein, I
Archives of gynecology and obstetrics, ISSN 0932-0067, 11/2014, Volume 290, Issue 5, pp. 839 - 842
Human Genetics | Peritoneal | Medicine & Public Health | Gynecology | Fallopian tube cancer | Obstetrics/Perinatology | FIGO classification | Endocrinology | Ovarian cancer | Cancer | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Peritoneal Neoplasms - pathology | Lymph Nodes - pathology | Prognosis | Humans | Peritoneal Neoplasms - surgery | Ovarian Neoplasms - pathology | Fallopian Tube Neoplasms - pathology | Cystadenocarcinoma, Serous - pathology | Neoplasm Staging - methods | Ovarian Neoplasms - classification | Animals | Fallopian Tube Neoplasms - surgery | Adult | Female | Peritoneal Neoplasms - classification | Adenocarcinoma, Clear Cell - pathology | Carcinoma - pathology | Fallopian Tube Neoplasms - classification | Ovarian Neoplasms - surgery | Pelvic Neoplasms - pathology | Lymphatic system | Metastasis | Classification | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights